Skip to content

Study · Case report or series · n = 1 · 1998

5 results

Secondary central precocious puberty in a girl with McCune-Albright syndrome responds to treatment with GnRH analogue.

Schmidt H, Kiess W

Journal of pediatric endocrinology & metabolism : JPEM1 Jan 1998Cited by 15 (Europe PMC)

PMID9642633 (opens in a new tab)DOI10.1515/jpem.1998.11.1.77 (opens in a new tab)PepBankPUB-09642633
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a girl with McCune-Albright syndrome, bone age was 12 years after three years of triptorelin.

    In plain wordsIn a girl with McCune-Albright syndrome, bone age was 12 years after three years of triptorelin.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Direction not reportedBone age
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.75 mg every four weeks, then every three weeks · intramuscular · 3 yearsAs given in this study (human).

    Measurements

    Bone age
    12 yr
    three years after treatment start

    Source sentences

    Summary
    Three years after the start of treatment bone age was 12 yr and growth velocity was 2.5 cm/year.
    2 context sentences
    Summary · context
    In contrast, we have successfully treated a young girl with MAS and--probably secondary--central precocious puberty using Decapeptyl, a long acting GnRH analogue.
    Summary · context
    Therapy was started with 3.75 mg GnRH analogue i.m. every four weeks and was intensified two years after the beginning of therapy to 3.75 mg i.m. every three weeks.
  2. 02HumanCase report or seriesEfficacy outcome

    In a girl with McCune-Albright syndrome, growth velocity was 2.5 cm/year after three years of triptorelin.

    In plain wordsIn a girl with McCune-Albright syndrome, growth velocity was 2.5 cm/year after three years of triptorelin.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Direction not reportedGrowth velocity
    Study

    n = 1

    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    3.75 mg every four weeks, then every three weeks · intramuscular · 3 yearsAs given in this study (human).

    Measurements

    Growth velocity
    2.5 cm/year
    three years after treatment start

    Source sentences

    Summary
    Three years after the start of treatment bone age was 12 yr and growth velocity was 2.5 cm/year.
    2 context sentences
    Summary · context
    In contrast, we have successfully treated a young girl with MAS and--probably secondary--central precocious puberty using Decapeptyl, a long acting GnRH analogue.
    Summary · context
    Therapy was started with 3.75 mg GnRH analogue i.m. every four weeks and was intensified two years after the beginning of therapy to 3.75 mg i.m. every three weeks.
  3. 03HumanCase report or seriesEfficacy outcome

    In a girl with McCune-Albright syndrome, Tanner stage remained B3, PH3 during triptorelin treatment.

    In plain wordsIn a girl with McCune-Albright syndrome, puberty stage remained unchanged during triptorelin treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeTanner stage
    Study

    n = 1

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.75 mg every four weeks, then every three weeks · intramuscular · 3 yearsAs given in this study (human).

    Source sentences

    Summary
    Tanner stage was B3, PH3 and LHRH testing revealed biochemical evidence for suppression of gonadotropins: LH < 0.5/1.0, FSH 1.9/2.5 (mU/ml).
    3 context sentences
    Summary · context
    At initial presentation height was 130.7 cm (> 97 percentile), weight 27.5 kg (> 97 percentile), Tanner stage B3, PH3.
    Summary · context
    In contrast, we have successfully treated a young girl with MAS and--probably secondary--central precocious puberty using Decapeptyl, a long acting GnRH analogue.
    Summary · context
    Therapy was started with 3.75 mg GnRH analogue i.m. every four weeks and was intensified two years after the beginning of therapy to 3.75 mg i.m. every three weeks.
  4. 04HumanCase report or seriesEfficacy outcome

    In a girl with McCune-Albright syndrome, LHRH testing showed LH suppression during triptorelin treatment.

    In plain wordsIn a girl with McCune-Albright syndrome, testing showed suppressed LH during triptorelin treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseLH suppression
    Study

    n = 1

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.75 mg every four weeks, then every three weeks · intramuscular · 3 yearsAs given in this study (human).

    Measurements

    LH
    < 0.5 mU/ml
    LHRH test after 3 years of treatment, first of two reported values
    LH
    1 mU/ml
    LHRH test after 3 years of treatment, second of two reported values

    Source sentences

    Summary
    Tanner stage was B3, PH3 and LHRH testing revealed biochemical evidence for suppression of gonadotropins: LH < 0.5/1.0, FSH 1.9/2.5 (mU/ml).
    2 context sentences
    Summary · context
    In contrast, we have successfully treated a young girl with MAS and--probably secondary--central precocious puberty using Decapeptyl, a long acting GnRH analogue.
    Summary · context
    Therapy was started with 3.75 mg GnRH analogue i.m. every four weeks and was intensified two years after the beginning of therapy to 3.75 mg i.m. every three weeks.
  5. 05HumanCase report or seriesEfficacy outcome

    In a girl with McCune-Albright syndrome, LHRH testing showed FSH suppression during triptorelin treatment.

    In plain wordsIn a girl with McCune-Albright syndrome, testing showed suppressed FSH during triptorelin treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseFSH suppression
    Study

    n = 1

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.75 mg every four weeks, then every three weeks · intramuscular · 3 yearsAs given in this study (human).

    Measurements

    FSH
    1.9 mU/ml
    LHRH test after 3 years of treatment, first of two reported values
    FSH
    2.5 mU/ml
    LHRH test after 3 years of treatment, second of two reported values

    Source sentences

    Summary
    Tanner stage was B3, PH3 and LHRH testing revealed biochemical evidence for suppression of gonadotropins: LH < 0.5/1.0, FSH 1.9/2.5 (mU/ml).
    2 context sentences
    Summary · context
    In contrast, we have successfully treated a young girl with MAS and--probably secondary--central precocious puberty using Decapeptyl, a long acting GnRH analogue.
    Summary · context
    Therapy was started with 3.75 mg GnRH analogue i.m. every four weeks and was intensified two years after the beginning of therapy to 3.75 mg i.m. every three weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.